计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC 50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects
In Vitro
PD-1/PD-L1-IN-NP19 (compound NP19) (0.37-10 μM; 72 h) significantly elevates the production of IFN-γ in a dose dependent manner from T cells co-cultured with tumor cells. PD-1/PD-L1-IN-NP19 exhibits much lower activity for inhibiting mouse PD-1/PD-L1 interaction with an IC 50 in the micromolar range (>1µM), as compared to the inhibition of human PD1/PD-L1 interaction (IC 50 =12.5 nM). PD-1/PD-L1-IN-NP19 (10 µM; 48 h) displays no apparent cytotoxic effects on A549, MCF-7, and B16-F10 cells at a concentration of 10 µM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
PD-1/PD-L1-IN-NP19 (compound NP19) (25-100 mg/kg; intragastric gavage once daily for 15 d) inhibits the growth of melanoma tumors dramatically in mice . PD-1/PD-L1-IN-NP19 (25 mg/kg; i.p. daily for 14 d) demonstrates significant antitumor efficacy with a tumor growth inhibition (TGI) of 76.5% and is well tolerated in an H22 hepatoma mouse model . PD-1/PD-L1-IN-NP19 (1 mg/kg; i.v.) shows the half time (t 1/2 =1.5±0.5 h), clearance rate (CL=0.9±0.2 L/h/kg) and apparent distribution volume (Vss=2.1±0.5 L/kg) in rats . PD-1/PD-L1-IN-NP19 (10 mg/kg; p.o.) shows the oral absorption (T max =0.6±0.2 h), long half-life (t 1/2 =10.9±7.7 h) and oral bioavailability (F=5%) in rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BALB/c mice (6-8 weeks) with B16-F10 melanoma tumors Dosage: 25, 50, 100 mg/kg Administration: Intragastric gavage once daily for 15 days Result: Inhibited the growth of melanoma tumors up to 51.1, 75 and 80.9% at dose of 25, 50, 100 mg/kg, respectively. Exhibited normal physical activity and increased body weights slightly. Animal Model: Male Sprague-Dawley rats Dosage: 1 mg/kg for i.v. and 10 mg/kg for p.o. (Pharmacokinetic Analysis) Administration: I.v. and p.o. Result: I.v.: t 1/2 =1.5 h; C max =1751 μg/L; CL=0.9 L/h/kg. P.o.: t 1/2 =10.9 h; C max =69.5 μg/L; CL=23.1 L/h/kg.
Form:Solid
IC50& Target:IC50: 12.5 nM (human PD-1/PD-L1)
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机酸及其衍生物 |
| 类(Class) | 羧酸及其衍生物 |
| 亚类(Subclass) | 氨基酸、肽和类似物 |
| 中间层级节点(Intermediate Tree Nodes) | 氨基酸及其衍生物 |
| 直接上位类(Direct Parent) | α氨基酸及其衍生物 |
| 其他上位类(Alternative Parents) | 苯氧基化合物 酚醚 苯腈 氯苯类 烷基芳基醚 氨基酸 腈类 一元羧酸及其衍生物 二烷基胺 羧酸 有机光子化合物 有机氯化物 有机氧化物 碳氢化合物衍生物 |
| 分子骨架(Molecular Framework) | 芳香族同单环化合物 |
| 取代基(Substituents) | 芳基醚 - α-氨基酸或其衍生物 - 氨基酸 - 氨基酸 - 芳香族同单环化合物 - 苯基化合物 - 苯甲腈 - 羧酰胺基 - 氯苯 - 乙醚 - 卤苯 - 烃衍生物 - 单羧酸或其衍生物 - 单环苯基基团 - 氰基化合物 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氯化物 - 有机卤化物 - 有机氮化合物 - 有机氧化合物 - 有机氮化合物 - 苯酚醚 - 苯氧基化合物 - 二级脂肪胺 - 醛基 |
| 描述(Description) | 该化合物属于α-氨基酸及其衍生物类有机化合物。这类氨基酸的氨基连接在羧基团直接相邻的碳原子(α碳)上,或其衍生物。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|